As­traZeneca, Dai­ichi’s TROP2 drug miss­es over­all sur­vival goal in Phase 3 breast can­cer tri­al

As­traZeneca and Dai­ichi Sankyo’s TROP2-di­rect­ed an­ti­body-drug con­ju­gate failed a key sur­vival end­point in a late-phase breast can­cer study, po­ten­tial­ly throw­ing a wrench in­to its on­go­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER